CORRECTION Open Access



Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells

Manabu Emi¹, Ryungsa Kim^{2*}, Kazuaki Tanabe¹, Yoko Uchida¹ and Tetsuya Toge¹

Correction to: Breast Cancer Res https://doi.org/10.1186/bcr1323

After the publication of this work [1] errors were noticed in Figs. 1a, 6a, and 8a—in which the β -actin bands were mistakenly presented. The corrected Figs. 1, 6, and 8 are presented below. The correction does not affect our conclusions. Nevertheless, we apologize for this error.

Author details

¹Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. ²International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Received: 22 January 2019 Accepted: 22 January 2019 Published online: 17 February 2019

Reference

 Emi, et al. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005;7:R940. https://doi.org/10.1186/bcr1323.

²International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan Full list of author information is available at the end of the article



^{*} Correspondence: rkim@hiroshima-u.ac.jp

Emi et al. Breast Cancer Research (2019) 21:26 Page 2 of 4




Fig. 1 Expression levels of Bcl-2 and Bcl-xL proteins in MDA-MB-231, MDA MD-453, BT-474, and ZR-75-1 cells. **a** Western blot analysis of Bcl-2 and Bcl-xL expression. **b** Quantification of Bcl-2 and Bcl-xL expression by densitometric analysis. The relative expression of Bcl-2 and BclxL in MDA-MB-453 cells was compared with the expression in MDAMB-231, BT-474, and ZR-75-1 cells. Results are from two representative, independent experiments

Emi et al. Breast Cancer Research (2019) 21:26 Page 3 of 4




Fig. 6 Effects of treatment with antisense *Bcl-2* and mitomycin C, doxorubicin, paclitaxel, or docetaxel on BT-474 cells. **a** Expression levels of Bcl-2 and Bcl-xL protein in BT-474 cells transplanted into athymic mice after treatment with antisense (AS) *Bcl-2* oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. **b** Enhancement of the antitumor effects of anticancer drugs by AS *Bcl-2* ODNs in BT-474 tumor xenografts. Each point represents the mean tumor volume of the eight mice in each group. Error bars indicate SD. *, P < 0.05, analysis of variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxoru- bicin;TXL, paclitaxel; TXT, docetaxel

Emi et al. Breast Cancer Research (2019) 21:26 Page 4 of 4




Fig. 8 Effects of treatment with antisense *Bcl-xL* and mitomycin C, doxorubicin, paclitaxel, or docetaxel on MDA-MB-231 cells. **a** Expression levels of Bcl-xL and Bcl-2 protein in MDA-MB-231 cells transplanted into athymic mice after treatment with antisense (AS) *Bcl-xL* oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. **b** Enhancement of the antitumor effects of anticancer drugs by AS *Bcl-xL* ODNs in MDA-MB-231 tumor xenografts. Each point represents the mean tumor volume of the four mice in each group. Error bars indicate SD. *, P< 0.05, analysis of variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxorubicin; TXL, paclitaxel; TXT, docetaxel